STRUCTURE-ACTIVITY-RELATIONSHIPS OF ANTINEOPLASTIC AGENTS IN MULTIDRUG RESISTANCE

被引:51
作者
SELASSIE, CD
HANSCH, C
KHWAJA, TA
机构
[1] UNIV SO CALIF,SCH MED,CTR COMPREHENS CANC,LOS ANGELES,CA 90033
[2] UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033
关键词
D O I
10.1021/jm00169a014
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Clinical resistance to many antineoplastic agents is a major cause of treatment failure. The well-documented phenomenon addressed as multidrug resistance (MDR) allows cells to withstand exposure to lethal doses of drugs with dissimilar chemical structures, modes of action, and physicochemical properties. In one of the earliest studies on MDR, Biedler and Rielun in an attempt to explain the cross-resistance profile of actinomycin D resistant Chinese hamster cells suggested that molecular weight was an important determinant. Our statistical analysis of their data validates their claim and indeed strongly demonstrates that cross resistance is enhanced by the increased size and hydrophobicity of the antitumor agent. Our preliminary studies with methotrexate-resistant L1210 cells indicates that cross resistance is increased in the case of moderatesized, hydrophilic drugs. These two studies and others suggest that current chemotherapy regimens may be improved by treating resistant cells with antineoplastic agents displaying physicochemical characteristics opposite to that of the original inducing agent. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:1914 / 1919
页数:6
相关论文
共 25 条
[1]  
ARSENAULT LA, 1988, BIOCHIM BIOPHYS ACTA, V938, P315
[2]   PLEIOTROPIC PHENOTYPE OF COLCHICINE-RESISTANT CHO CELLS - CROSS-RESISTANCE AND COLLATERAL SENSITIVITY [J].
BECHHANSEN, NT ;
TILL, JE ;
LING, V .
JOURNAL OF CELLULAR PHYSIOLOGY, 1976, 88 (01) :23-31
[3]  
BECK WT, 1979, CANCER RES, V39, P2070
[4]  
BEIDLER JL, 1981, MOL ACTIONS TARGETS, P453
[5]  
BIEDLER JL, 1970, CANCER RES, V30, P1174
[6]  
CONTER V, 1984, CANCER TREAT REP, V68, P831
[7]   ACTIVE OUTWARD TRANSPORT OF DAUNOMYCIN IN RESISTANT EHRLICH ASCITES TUMOR-CELLS [J].
DANO, K .
BIOCHIMICA ET BIOPHYSICA ACTA, 1973, 323 (03) :466-483
[8]  
DUVE CD, 1974, BIOCHEM PHARMACOL, V23, P2495
[9]  
ELIOTT EM, 1981, CANCER RES, V41, P393
[10]  
GERLACH JH, 1986, CANCER SURV, V5, P25